Literature DB >> 9105581

Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats.

I Khromova1, T Voronina, V A Kraineva, N Zolotov, P T Männistö.   

Abstract

The effects of new selective catechol-O-methyltransferase (COMT) inhibitors entacapone (mainly peripheral effect) and tolcapone (acting also in the brain) on normal and impaired cognitive functions were studied in aversively motivated inhibitory avoidance using a single-trial passive avoidance paradigm in young adult rats. Passive avoidance retention latency was shortened by either scopolamine (1.0 mg/kg) or bilateral lesions to nucleus basalis magnocellularis (NBM) caused by infusions of ethylcholine aziridinium (AF64A). Entacapone (30 mg/kg) administered once before training or before the retention test, 24 h after training, prevented the effect of scopolamine but did not alter extinction in these rats. However, entacapone (30 mg/kg) prolonged lag time when given during the extinction process to intact rats after training. Tolcapone administered once before training (10 mg/kg) counteracted the effect of scopolamine. It prolonged retention latency of the intact rats when given after training (10 mg/kg). Tolcapone (3 mg/kg) also prolonged lag time when given during extinction to rats bearing NBM lesions. The effect of scopolamine on extinction and retrieval was not prevented by tolcapone. Only entacapone improved memory storage. Collectively, the present results indicate that COMT inhibitors prolong retention latencies in a single-trial passive avoidance test assessed at several memory phases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9105581     DOI: 10.1016/s0166-4328(96)02242-5

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  7 in total

1.  Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice.

Authors:  Eric R Detrait; Greg V Carr; Daniel R Weinberger; Yves Lamberty
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

Review 2.  Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

Authors:  S Kaakkola
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

3.  BDNF and COMT polymorphisms: relation to memory phenotypes in young adults with childhood-onset mood disorder.

Authors:  J Strauss; C L Barr; C J George; C M Ryan; N King; S Shaikh; M Kovacs; J L Kennedy
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 4.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex.

Authors:  C C Lapish; S Ahn; L M Evangelista; K So; J K Seamans; A G Phillips
Journal:  Psychopharmacology (Berl)       Date:  2008-10-15       Impact factor: 4.530

6.  Entacapone promotes hippocampal neurogenesis in mice.

Authors:  Dae Young Yoo; Hyo Young Jung; Woosuk Kim; Kyu Ri Hahn; Hyun Jung Kwon; Sung Min Nam; Jin Young Chung; Yeo Sung Yoon; Dae Won Kim; In Koo Hwang
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

7.  Catechol-o-methyltransferase inhibitor tolcapone improves learning and memory in naïve but not in haloperidol challenged rats.

Authors:  Anita Mihaylova; Hristina Zlatanova; Nina Doncheva; Delian Delev; Ilia Kostadinov
Journal:  Iran J Basic Med Sci       Date:  2019-06       Impact factor: 2.699

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.